| Literature DB >> 29506474 |
Tzu-Chun Tsai1, Chun-Che Shih1,2, Hsin-Ping Chien3, An-Hang Yang1,2, Jenn-Kan Lu4,5, Jen-Her Lu6,7,8.
Abstract
BACKGROUND: Tbx5 deficiency in zebrafish causes several abnormal phenotypes of the heart and pectoral fins. It has been reported that exogenous human growth hormone can enhance expression of downstream mediators in the growth hormone and insulin-like growth factor I (IGF-I) pathway and partially restore dysmorphogenesis in tbx5 morphants. This study aimed to further evaluate the effects of IGF-I on cell apoptosis and dysmorphogenesis in zebrafish embryos deficient for tbx5.Entities:
Keywords: Apoptosis; Holt-Oram syndrome; Insulin-like growth factor I; Zebrafish; tbx5
Mesh:
Substances:
Year: 2018 PMID: 29506474 PMCID: PMC5836385 DOI: 10.1186/s12861-017-0161-1
Source DB: PubMed Journal: BMC Dev Biol ISSN: 1471-213X Impact factor: 1.978
Results of microarray analysis of tbx5 knockdown zebrafish embryos
| GenBank Accession | Gene Symbol | Gene Name | Biological Process | Stages | Reference |
|---|---|---|---|---|---|
| Up-regulated genes a | |||||
| NM_131188 |
| myosin, light polypeptide 2, skeletal muscle | phosphorylation | 24 | Xu Y, et al. 2010 |
| NM_178436 |
| MCM5 minichromosome maintenance deficient 5 ( | cell cycle, apoptosis | 30 | Soojin Ryu, et al. 2005 |
| NM_130925 |
| KH domain containing, RNA binding, signal transduction associated 1 | cell cycle, phosphorylation | 24,30 | Paronetto MP, et al. 2011 |
| NM_130926 |
| non-metastatic cells 2, protein (NM23B) expressed in | cell cycle, phosphorylation | 30,48 | Prakash T, et al. 2010 |
| NM_131404 |
| proliferating cell nuclear antigen | cell cycle | 24,30,48 | Sapna D B, et al. 2010 |
| NM_200650 |
| protein arginine methyltransferase 1 | cell cycle, apoptosis | 24,30,48 | A. Scoumanne, et al. 2009 |
|
| |||||
| NM_201153 |
| ribosomal protein S3 | cell cycle, apoptosis | 24,30,48 | Sang Bae Lee, et al. 2010 |
| NM_214793 |
| ribosomal protein S8 | apoptosis | 30 | Hao Y, et al. 2011 |
| NM_200750 |
| ribosomal protein S19 | cell cycle, apoptosis, | 24,30,48 | K. Miyake, et al.2008 |
|
| |||||
| NM_001003844 |
| ribosomal protein L6 | cell cycle | 30,48 | Wu Q, Gou Y, Wang Q, Jin H, Cui L, et al. 2011 |
| NM_213644 |
| ribosomal protein L7 | cardiac myogenesis, cell cycle, apoptosis | 24,30,48 | Neumann F, et al. 1995 |
| NM_212784 |
| ribosomal protein L13a | apoptosis | 24,30,48 | Hu, B., et al. 2009 |
| NM_213107 |
| ribosomal protein L4 | cardiac myogenesis, apoptosis | 24,30,48 | Zhu, H, et al. 2007 |
| Down-regulated genes a | |||||
| NM_001001832 |
| intraflagellar transport protein 57 | apoptosis | 30,48 | Sarmah B. |
| NM_001020710 |
| protein serine kinase H1 | phosphorylation | 30,48 | Brede G., et al. 2003 |
| NM_001003738 |
| cytokine induced apoptosis inhibitor 1 | cell cycle, apoptosis | 30,48 | Li X, Hao Z, Fan R |
| NM_001077567 |
| eukaryotic translation initiation factor 2-alpha kinase 1 | phosphorylation | 30,48 | Rothenburg S, et al. 2005 |
| NM_001013443 |
| eukaryotic translation initiation factor 4, gamma 2b | apoptosis | 30,48 | Nousch, M., Reed, V., et al. 2007 |
| NM_001030253 |
| B-cell leukemia/lymphoma 2 | apoptosis | 30,48 | Kratz, E., et al. 2006 |
| NM_131837 |
| CCAAT/enhancer binding protein (C/EBP) 1 | cell cycle | 30,48 | Kitaguchi, T., et al. 2009 |
| NM_199784 |
| e2f-associated phosphoprotein | apoptosis | 30,48 | Novy M. |
| NM_001102387 |
| NADPH oxidase 1 | cardiac myogenesis | 30,48 | Jian Li, et al. 2006 |
| NM_182885 |
| protocadherin 10b | cell cycle | 30,48 | Murakami, T., et al. 2006 |
| NM_200348 |
| cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) | cardiac myogenesis, cell cycle | 30,48 | Bai, X., et al. 2004 |
| NM_173236 |
| histone deacetylase 1 | cell cycle, apoptosis | 24,48 | Burns, C.E., et al. 2009 |
| NM_199481 |
| cyclin G1 | cell cycle | 24,48 | Newman, M., et al. 2009 |
| NM_001002198 |
| BTB (POZ) domain containing 9 | cell cycle | 24,30,48 | Schormair B, et al. 2011 |
| NM_001079826 |
| BH3 interacting domain death agonist | apoptosis | 24,30,48 | Kratz, E |
| NM_001039634 |
| Wilms tumor 1b | apoptosis | 24,30,48 | Perner B, et al. 2007 |
| NM_198146 |
| v-akt murine thymoma viral oncogene homolog 2 | apoptosis, phosphorylation | 24,30,48 | Jensen, P.J., et al. 2010 |
| NM_131390 |
| glycogen synthase kinase 3 alpha | cardiac mophogenesis | 24,30,48 | Lee, H.C., et al. 2007 |
aThe expression of genes in the WT group was taken as the reference of 1. If the expression of a gene in the MO group and in the MOIGF1 group were both higher than 1.5 folds of that in the WT group, the gene would be marked as “up-regulation”. Conversely, if the expression of a gene in the MO group and in the MOIGF1 group were both lower than 1.5 folds of that in the WT group, the gene would be marked as “down-regulation”
Fig. 1Expression levels of myocardium-related genes and cardiomyocyte proteins in wild-type embryos and tbx5 morphants. The MO group had significantly decreased expression of myocardium-related genes (mef2c, ndrg4, cx43) during the embryonic development stages (24 hpf (a), 30 hpf (b), and 48 hpf (c)) compared with the WT group. Zebrafish embryos at 30 hpf were stained with the myosin heavy chain antibody MF20 (green), connexin-43 antibody Cx43 (green), myocyte enhancer factor-2 antibody MEF2 (green) and counterstained with DAPI (blue) for nucleus identification. The MO group had decreased expression of MF20 (d), Cx43 (e), and MEF2 (f) compared to the WT group. Data are presented as the means ± standard deviations. *P < 0.05 vs. WT. WT, wild-type embryos; MO, tbx5 morphants. Hpf: hours post-fertilization. The number of specimens was 50, and the number of independent experiments was 3 in each group
Fig. 2Expression of igf1, igf1-ra, igf1-rb in the tbx5 morphants and IGF-I treated-tbx5 morphants. Expression levels of igf1 (a), igf1-ra (b) and igf1-rb (c) were reduced significantly in the MO group throughout all developmental stages. The WTIGF1 and MIS group had similar expression levels as the WT group. Expression of igf1 in the MOIGF1 group was partially restored and significantly higher than that in the MO group. Data are presented as the means ± standard deviations. *P < 0.05 vs. WT; #P < 0.05 MOIGF1 vs. MO. WT: wild-type embryos; MO: tbx5 morphants; MIS: mismatch tbx5 morpholino-treated wild-type embryos; WTIGF1: IGF-I-treated wild-type embryos; MOIGF1: IGF-I-treated tbx5 morphants; hpf: hours post-fertilization. The number of specimens was 50, and the number of independent experiments was 3 in each group
Fig. 3Phenotypes of the tbx5 morphants and IGF-I-treated tbx5 morphants. The WT (a) and MIS groups (b) had normal hearts, and the WTIGF1 (c) group had minimal pericardial effusion. The MO group (d) had string-like hearts accompanied by a massive pericardial edema, but the appearance of hearts in the MOIGF1 group (e) was improved. There were no significant differences observed in the trunks of the WT (f), MIS (g) and WTIGF1 groups (i), in which the trunks were straight and the somites appeared to be “V-shaped”. The trunk of the MO group (h) bent severely and showed a “U shape”. The MOIGF1 group (j) had partially-restored appearances of the trunks and curvatures of somites. The pectoral fins of the MO group (m) were truncated or undeveloped, but the WT (k), MIS (l), WTIGF1 (n), and the MOIGF1 group (o) had normal pectoral fins. The MO group had significantly lower normal morphology rates of the hearts (p), trunks (q) and pectoral fins (r). Compared with the MO group, the MOIGF1 group had significantly higher percentages of normal morphology rates of the hearts (p), trunks (q) and pectoral fins. No defective embryos were found in the WT and MIS group, and almost all of the WTIGF1 group embryos developed well. Red arrow: pericardial effusion; black arrow head: defect site; dashed line: shape of somite border. Data are presented as the means ± standard deviations. *P < 0.05 vs. WT; #P < 0.05 MOIGF1 vs. MO. WT: wild-type embryos; MO: tbx5 morphants; MIS: mismatch tbx5 morpholino-treated wild-type embryos; WTIGF1: IGF-I-treated wild-type embryos; MOIGF1: IGF-I-treated tbx5 morphants; hpf: hours post-fertilization. The number of specimens was 50, and the number of independent experiments was 3 in each group
Fig. 4Expression levels of phosphorylation-related genes and proteins in the IGF-I pathway in the tbx5 morphants and IGF-I-treated tbx5 morphants. The mRNA expression levels of erk1 (a) and akt2 (b) were reduced significantly in the MO group and restored in the MOIGF1 group. Expression of the ERK1 and AKT2 proteins was significantly reduced in the MO group at 48 hpf but was restored in the MOIGF1 group (c). Data are presented as the means ± standard deviations. *P < 0.05 vs. WT; #P < 0.05 MOIGF1 vs. MO. WT: wild-type embryos; MO: tbx5 morphants; MIS: mismatch tbx5 morpholino-treated wild-type embryos; WTIGF1: IGF-I-treated wild-type embryos; MOIGF1: IGF-I-treated tbx5 morphants; hpf: hours post-fertilization. The number of specimens was 50, and the number of independent experiments was 3 in each group
Fig. 5Expression of apoptosis proteins and genes in the tbx5 morphants and IGF-I-treated tbx5 morphants. Expression of the bad gene was significantly induced in the MO group (a) at 24 and 30 hpf, and the expression of bcl2 was significantly induced in the MO group at 24, 30 and 48 hpf. b. There were no significant differences in the expression levels of bad and bcl2 between the WT, WTIGF1 and MOIGF1 groups. Zebrafish embryos at 30 hpf were stained by the proapoptotic-related antibody BAD (red) and anti-apoptotic related antibody BCL2 (red) and were counterstained with DAPI (blue) for nuclear observation. Expression levels in the sagittal sections of hearts are shown in C1–3 and E1–3; expression levels in the transverse sections of pectoral fins are shown in D1–3 and F1–3. The WT group had very low expression of the BAD apoptotic protein (Figure 6C1, 6D1) and BCL2 pro-apoptotic protein (Figure 6E1, 6F1). Expression of the BAD apoptotic protein (Figure 6C2, 6D2) and BCL2 pro-apoptotic protein (Figure 6E2, 6F2) was induced significantly in hearts and pectoral fins in the MO group, whereas expression of BAD (Figure 6C3, 6D3) and BCL2 (Figure 6E3, 6F3) was significantly reduced in the MOIGF1 group. Data are presented as the means ± standard deviations. *P < 0.05 vs WT. WT: wild-type embryos; MO: tbx5 morphants; MIS: mismatch tbx5 morpholino-treated wild-type embryos; WTIGF1: IGF-I-treated wild-type embryos; MOIGF1: IGF-I-treated tbx5 morphants; hpf: hours post-fertilization. The number of specimens was 50, and the number of independent experiments was 3 in each group
Fig. 6TUNEL assay for the tbx5 morphants and IGF-I-treated tbx5 morphants. TUNEL assay revealed no TUNEL-positive cells in the WT (a), MIS (b), and WTIGF1 (c) groups. However, massive numbers of TUNEL-positive cells were visible in the MO group (d). In the MOIGF1 group, the amount of TUNEL-positive cells was reduced (e). Most of the TUNEL-positive cells were clustered over the tail and trunk, while several were be found over the yolk sac and head (f). Arrow, TUNEL-positive cells. Data are presented as the means ± standard deviations. WT: wild-type embryos; MO: tbx5 morphants; MIS: mismatch tbx5 morpholino-treated wild-type embryos; WTIGF1: IGF-I-treated wild-type embryos; MOIGF1: IGF-I-treated tbx5 morphants. The number of specimens was 10, and the number of independent experiments was 3 in each group
Fig. 7Survival of the tbx5 morphants and IGF-I-treated tbx5 morphants. The embryos were examined longitudinally under a microscope for up to 96 hpf. The survival rate of the WT group at 96 hpf was approximately 90%. The MIS and WTIGF1 groups had similar survival rates as the WT group. The MO group had the lowest survival rate, and the survival rate of the MOIGF1 group was significantly improved. WT: wild-type embryos; MO: tbx5 morphants; MIS: mismatch tbx5 morpholino-treated wild-type embryos; WTIGF1: IGF-I-treated wild-type embryos; MOIGF1: IGF-I- treated tbx5 morphants; hpf: hours post-fertilization. The number of specimens was 50, and the number of independent experiments was 3 in each group